Strengths
- Kindbody is an uncovered private unicorn at approximately $1.80B.
- Kindbody offers fertility, IVF, egg freezing, wellness and family-building care.
- Kindbody serves employer and health-plan channels as well as individuals.
Diligence report
Kindbody
Kindbody Startup Diligence Report
Proceed only if private diligence confirms clinic-level economics, cash runway, outcome quality, employer retention and credible remediation of independent allegations.
Company profile
Kindbody Startup Diligence Report
Kindbody remains eligible for this run based on CB Insights unicorn-list inclusion and active company-owned sources, but public evidence flags unusually high confirmatory diligence needs around valuation, cash runway, clinic operations, clinical quality, leadership continuity and reputational exposure.
- Website
- kindbody.com
- Sector
- Fertility, family-building benefits and women's health services
- Geography
- United States / national clinic and virtual-care network
- Stage
- Private unicorn / growth-stage company
- Known aliases
- Kindbody, Kindbody Inc.
- Report version
- 1.0
- Timezone
- UTC
Executive summary
Risks
- Financial runway and valuation support may be impaired
- Clinical quality and patient-safety allegations
- Customer concentration and utilization are not public
Gaps
- Audited/management financials, current runway, debt and cap table.
- Clinic-level P&Ls, patient outcomes, adverse-event logs and quality controls.
- Top employer/customer ARR, utilization, renewals and concentration.
- Leadership/org chart, attrition, compensation and roadmap ownership.
- Litigation/regulatory, HIPAA/security, insurance and material-contract schedules.
Risk register
R-001: Financial runway and valuation support may be impaired
Public reporting suggests financing pressure and potential valuation compression; financial statements and cash runway are private.
Diligence request: Request audited/management financials, latest financing documents, cash runway, debt and valuation support.
R-002: Clinical quality and patient-safety allegations
Bloomberg summarized allegations of clinical mistakes, staffing crises and financial pressures.
Diligence request: Require clinical quality audit, adverse-event logs, lab procedures, staffing ratios and malpractice/claims history.
R-004: Leadership and execution continuity risk
Public reporting described a temporary Office of the CEO and executive churn while the company pursues a new platform.
Diligence request: Interview management, review org chart, hiring plan, attrition and roadmap accountability.
R-005: Reputational and regulatory scrutiny in fertility services
Fertility care is sensitive; independent allegations and complex patient-data/HIPAA operations require counsel review.
Diligence request: Request litigation/regulatory schedule, HIPAA/security audits, insurance and patient complaint/adverse-event logs.
R-003: Customer concentration and utilization are not public
Covered lives and employer-client references do not disclose ARR concentration, utilization or churn.
Diligence request: Request top-customer ARR, utilization, NRR, churn and contract terms.
01Financial Information
Kindbody has public valuation/funding anchors, but audited financials, forecast support, cash runway, revenue quality, debt and cap-table details are not public.
I.A Annual and quarterly financial information for the past three years
not publicly verifiable confidence: low
Kindbody has public valuation/funding anchors, but audited financials, forecast support, cash runway, revenue quality, debt and cap-table details are not public.
Evidence gaps
- Request audited/management financial statements, KPI bridge, cash runway, debt schedule, cap table and financing documents for Kindbody.
- Private data-room records are required before relying on this public-source screen for investment or acquisition decisions.
Hidden risks
- Valuation and runway may not match the CB Insights row.
Follow-up questions
- Request audited/management financial statements, KPI bridge, cash runway, debt schedule, cap table and financing documents for Kindbody.
I.B Financial Projections
not publicly verifiable confidence: low
Kindbody has public valuation/funding anchors, but audited financials, forecast support, cash runway, revenue quality, debt and cap-table details are not public.
Evidence gaps
- Request audited/management financial statements, KPI bridge, cash runway, debt schedule, cap table and financing documents for Kindbody.
- Private data-room records are required before relying on this public-source screen for investment or acquisition decisions.
Hidden risks
- Valuation and runway may not match the CB Insights row.
Follow-up questions
- Request audited/management financial statements, KPI bridge, cash runway, debt schedule, cap table and financing documents for Kindbody.
I.C Capital Structure
not publicly verifiable confidence: low
Kindbody has public valuation/funding anchors, but audited financials, forecast support, cash runway, revenue quality, debt and cap-table details are not public.
Evidence gaps
- Request audited/management financial statements, KPI bridge, cash runway, debt schedule, cap table and financing documents for Kindbody.
- Private data-room records are required before relying on this public-source screen for investment or acquisition decisions.
Hidden risks
- Valuation and runway may not match the CB Insights row.
Follow-up questions
- Request audited/management financial statements, KPI bridge, cash runway, debt schedule, cap table and financing documents for Kindbody.
| item | public signal | diligence caveat | verification status |
|---|---|---|---|
| Cap table | Investors named in CB Insights and company release | Ownership, liquidation preferences, debt and option pool are private | not_publicly_verifiable |
| Revenue and unit economics | Employer/health-plan positioning and covered-lives claim | ARR, gross margin, clinic contribution, cash burn and AR aging are private | not_publicly_verifiable |
I.D Other financial information
partially verified confidence: medium
Kindbody has public valuation/funding anchors, but audited financials, forecast support, cash runway, revenue quality, debt and cap-table details are not public.
Evidence gaps
- Request audited/management financial statements, KPI bridge, cash runway, debt schedule, cap table and financing documents for Kindbody.
- Private data-room records are required before relying on this public-source screen for investment or acquisition decisions.
Hidden risks
- Valuation and runway may not match the CB Insights row.
Follow-up questions
- Request audited/management financial statements, KPI bridge, cash runway, debt schedule, cap table and financing documents for Kindbody.
| date | round or event | amount | valuation or post money | investors or participants | verification status |
|---|---|---|---|---|---|
| 2023-03-02 | CB Insights unicorn date | not disclosed in tracker row | $1.80B | RRE Ventures; Google Ventures; Bramalea Partners | partially_verified |
| 2026-02-12 | Cumulative debt and equity funding statement | more than $315M | not disclosed | Perceptive Advisors; JP Morgan Chase Morgan Health; GV; RRE Ventures; others | partially_verified |
02Products
Public product pages verify an active product suite, but roadmap, margins, reliability, security and unit economics need private confirmation.
II.A Description of each product
partially verified confidence: medium
Public product pages verify an active product suite, but roadmap, margins, reliability, security and unit economics need private confirmation.
Evidence gaps
- Request product demos, architecture review, roadmap, security reports and gross-margin/unit-cost data.
- Private data-room records are required before relying on this public-source screen for investment or acquisition decisions.
Hidden risks
- Clinical quality and outcomes claims need audit.
Follow-up questions
- Request product demos, architecture review, roadmap, security reports and gross-margin/unit-cost data.
| product | audience | public evidence | verification status |
|---|---|---|---|
| Fertility treatment and IVF | Patients; employers; health plans | Company pages list IVF, conception care and clinical network | verified |
| Employer family-building benefits platform | Employers and members | 2026 release describes platform for employers, health plans and members | partially_verified |
| AI-enabled navigation and treatment planning | Employer clients and patients | Company announced AI intake, benefit transparency and predictor tools | partially_verified |
| offering | public price or model | competitor context | verification status |
|---|---|---|---|
| Patient fertility services | Company markets accessible pricing but detailed procedure prices vary | Competes with fertility clinic networks and benefits vendors | partially_verified |
| Large-employer savings model | Projected 2027 capped procedure pricing/shared-savings model | Carve-out fertility benefits and clinic networks | partially_verified |
03Customer Information
Public customer or partner signals exist, but revenue concentration, retention, churn, contract terms and top-customer identity are not publicly verifiable.
III.A Top customers by application
partially verified confidence: medium
Public customer or partner signals exist, but revenue concentration, retention, churn, contract terms and top-customer identity are not publicly verifiable.
Evidence gaps
- Request top-customer ARR, NRR/churn, cohort retention, customer contracts and reference calls.
- Private data-room records are required before relying on this public-source screen for investment or acquisition decisions.
Hidden risks
- Covered lives may not translate to utilization or revenue.
Follow-up questions
- Request top-customer ARR, NRR/churn, cohort retention, customer contracts and reference calls.
| customer or partner | relationship or use case | public evidence | revenue contribution public |
|---|---|---|---|
| Employer clients | Fertility/family-building benefits | Pilot phase with select employer clients representing over 3M covered lives | No |
| Health plans and individuals | Care delivery and benefit solution | Company describes employers, health plans and individuals as buyer/member groups | No |
III.B Strategic relationships
partially verified confidence: medium
Public customer or partner signals exist, but revenue concentration, retention, churn, contract terms and top-customer identity are not publicly verifiable.
Evidence gaps
- Request top-customer ARR, NRR/churn, cohort retention, customer contracts and reference calls.
- Private data-room records are required before relying on this public-source screen for investment or acquisition decisions.
Hidden risks
- Covered lives may not translate to utilization or revenue.
Follow-up questions
- Request top-customer ARR, NRR/churn, cohort retention, customer contracts and reference calls.
III.C Revenue by customer
not publicly verifiable confidence: low
Public customer or partner signals exist, but revenue concentration, retention, churn, contract terms and top-customer identity are not publicly verifiable.
Evidence gaps
- Request top-customer ARR, NRR/churn, cohort retention, customer contracts and reference calls.
- Private data-room records are required before relying on this public-source screen for investment or acquisition decisions.
Hidden risks
- Covered lives may not translate to utilization or revenue.
Follow-up questions
- Request top-customer ARR, NRR/churn, cohort retention, customer contracts and reference calls.
III.D Significant relationships severed within the last two years
not publicly verifiable confidence: low
Public customer or partner signals exist, but revenue concentration, retention, churn, contract terms and top-customer identity are not publicly verifiable.
Evidence gaps
- Request top-customer ARR, NRR/churn, cohort retention, customer contracts and reference calls.
- Private data-room records are required before relying on this public-source screen for investment or acquisition decisions.
Hidden risks
- Covered lives may not translate to utilization or revenue.
Follow-up questions
- Request top-customer ARR, NRR/churn, cohort retention, customer contracts and reference calls.
III.E Top suppliers
partially verified confidence: medium
Public customer or partner signals exist, but revenue concentration, retention, churn, contract terms and top-customer identity are not publicly verifiable.
Evidence gaps
- Request top-customer ARR, NRR/churn, cohort retention, customer contracts and reference calls.
- Private data-room records are required before relying on this public-source screen for investment or acquisition decisions.
Hidden risks
- Covered lives may not translate to utilization or revenue.
Follow-up questions
- Request top-customer ARR, NRR/churn, cohort retention, customer contracts and reference calls.
| supplier or dependency | role | public evidence | concentration risk |
|---|---|---|---|
| Partner IVF center network | Care access and geographic reach | Release names IVIRMA, Inception Fertility/Prelude Network and Ivy Fertility | Unknown contract terms and quality controls |
| Pharmacy/medication workflow | Medication fulfillment and treatment adherence | KindbodyRx and medication portal described publicly | Private pharmacy contracts and service levels required |
04Competition
The company operates in a competitive market where public evidence supports positioning but not win rates, switching costs or defensibility.
IV.A Competitive landscape by market segment
partially verified confidence: medium
The company operates in a competitive market where public evidence supports positioning but not win rates, switching costs or defensibility.
Evidence gaps
- Request win/loss, competitor displacement, pricing pressure and differentiation evidence.
- Private data-room records are required before relying on this public-source screen for investment or acquisition decisions.
Hidden risks
- Benefits-only competitors may have lower capital intensity.
Follow-up questions
- Request win/loss, competitor displacement, pricing pressure and differentiation evidence.
| competitor | segment | overlap | target differentiator | source basis |
|---|---|---|---|---|
| Progyny | Employer fertility benefits | Benefits navigation and employer channel | Kindbody owned/partner clinic network | Public positioning; no win-rate data |
| Maven Clinic / Carrot Fertility | Family benefits and virtual care | Employer benefits and member navigation | Direct clinic delivery and lab network | Analyst comparison from public category evidence |
| axis | target position | competitor pressure | evidence strength |
|---|---|---|---|
| Clinical control | Higher due to owned and partner clinics | Benefits-only vendors may be asset-light | medium |
| Capital intensity | High due to clinics/labs and clinical staffing | Asset-light competitors may have lower burn | medium |
05Marketing, Sales, and Distribution
Public GTM evidence shows active distribution channels, but CAC, quota productivity, pipeline conversion and budget adequacy are private.
V.A Strategy and implementation
partially verified confidence: medium
Public GTM evidence shows active distribution channels, but CAC, quota productivity, pipeline conversion and budget adequacy are private.
Evidence gaps
- Request pipeline by source, CAC/payback, quota attainment, sales-cycle, channel mix and marketing budget data.
- Private data-room records are required before relying on this public-source screen for investment or acquisition decisions.
Hidden risks
- Employer pipeline and savings claims may be unproven.
Follow-up questions
- Request pipeline by source, CAC/payback, quota attainment, sales-cycle, channel mix and marketing budget data.
| channel | region or buyer | public evidence | gap |
|---|---|---|---|
| Employer benefits sales | United States employers | Over 3M covered lives in select employer-client pilot context | Pipeline, ACV and renewal data |
| Direct patient clinics and virtual consults | US fertility patients | Company pages list scheduling, locations and virtual consultations | Utilization and conversion rates |
V.B Major Customers
partially verified confidence: medium
Public GTM evidence shows active distribution channels, but CAC, quota productivity, pipeline conversion and budget adequacy are private.
Evidence gaps
- Request pipeline by source, CAC/payback, quota attainment, sales-cycle, channel mix and marketing budget data.
- Private data-room records are required before relying on this public-source screen for investment or acquisition decisions.
Hidden risks
- Employer pipeline and savings claims may be unproven.
Follow-up questions
- Request pipeline by source, CAC/payback, quota attainment, sales-cycle, channel mix and marketing budget data.
V.C Principal avenues for generating new business
partially verified confidence: medium
Public GTM evidence shows active distribution channels, but CAC, quota productivity, pipeline conversion and budget adequacy are private.
Evidence gaps
- Request pipeline by source, CAC/payback, quota attainment, sales-cycle, channel mix and marketing budget data.
- Private data-room records are required before relying on this public-source screen for investment or acquisition decisions.
Hidden risks
- Employer pipeline and savings claims may be unproven.
Follow-up questions
- Request pipeline by source, CAC/payback, quota attainment, sales-cycle, channel mix and marketing budget data.
| signal | evidence | diligence request | verification status |
|---|---|---|---|
| Next-generation platform launch | PR Newswire release with employer, AI and clinical claims | Ask for adoption and ROI proof | partially_verified |
| Independent negative coverage | Bloomberg/Fertility Bridge risk coverage | Ask for company response, patient complaint logs and corrective actions | inconclusive |
V.D Sales force productivity model
not publicly verifiable confidence: low
Public GTM evidence shows active distribution channels, but CAC, quota productivity, pipeline conversion and budget adequacy are private.
Evidence gaps
- Request pipeline by source, CAC/payback, quota attainment, sales-cycle, channel mix and marketing budget data.
- Private data-room records are required before relying on this public-source screen for investment or acquisition decisions.
Hidden risks
- Employer pipeline and savings claims may be unproven.
Follow-up questions
- Request pipeline by source, CAC/payback, quota attainment, sales-cycle, channel mix and marketing budget data.
V.E Ability to implement marketing plan with current and projected budgets
not publicly verifiable confidence: low
Public GTM evidence shows active distribution channels, but CAC, quota productivity, pipeline conversion and budget adequacy are private.
Evidence gaps
- Request pipeline by source, CAC/payback, quota attainment, sales-cycle, channel mix and marketing budget data.
- Private data-room records are required before relying on this public-source screen for investment or acquisition decisions.
Hidden risks
- Employer pipeline and savings claims may be unproven.
Follow-up questions
- Request pipeline by source, CAC/payback, quota attainment, sales-cycle, channel mix and marketing budget data.
06Research and Development
Public sources reveal product and technical initiatives, but R&D spend, roadmap commitments and technical debt require management review.
VI.A Description of R&D organization
partially verified confidence: medium
Public sources reveal product and technical initiatives, but R&D spend, roadmap commitments and technical debt require management review.
Evidence gaps
- Request R&D budget, roadmap milestones, release quality metrics, incident history and technical-debt backlog.
- Private data-room records are required before relying on this public-source screen for investment or acquisition decisions.
Hidden risks
- AI and savings-model roadmap is execution-heavy.
Follow-up questions
- Request R&D budget, roadmap milestones, release quality metrics, incident history and technical-debt backlog.
| person or role | public role | background or signal | verification status |
|---|---|---|---|
| David Stern | CEO quoted in 2026 platform release | Leadership accountability for next-generation platform | verified |
| Clinical leadership team | Senior reproductive medicine and benefits expertise | Company claims 60+ years reproductive medicine and 70+ years benefits/commercial expertise | partially_verified |
VI.B New Product Pipeline
partially verified confidence: medium
Public sources reveal product and technical initiatives, but R&D spend, roadmap commitments and technical debt require management review.
Evidence gaps
- Request R&D budget, roadmap milestones, release quality metrics, incident history and technical-debt backlog.
- Private data-room records are required before relying on this public-source screen for investment or acquisition decisions.
Hidden risks
- AI and savings-model roadmap is execution-heavy.
Follow-up questions
- Request R&D budget, roadmap milestones, release quality metrics, incident history and technical-debt backlog.
| project | status | expected timing | public evidence |
|---|---|---|---|
| AI-enabled intake and navigation | Announced | 2026 pilot | Company release describes AI-powered care navigator |
| Large-employer savings model | Planned | 2027 | Company release says model will introduce capped procedure pricing and savings guarantee |
07Management and Personnel
Public team signals are available, but current org chart, compensation, retention, headcount plan and employee-relations records are private.
VII.A Organization Chart
partially verified confidence: medium
Public team signals are available, but current org chart, compensation, retention, headcount plan and employee-relations records are private.
Evidence gaps
- Request org chart, HRIS export, compensation plans, option grants, attrition data and employee-relations matters.
- Private data-room records are required before relying on this public-source screen for investment or acquisition decisions.
Hidden risks
- Leadership churn may affect execution.
Follow-up questions
- Request org chart, HRIS export, compensation plans, option grants, attrition data and employee-relations matters.
VII.B Historical and projected headcount by function and location
partially verified confidence: medium
Public team signals are available, but current org chart, compensation, retention, headcount plan and employee-relations records are private.
Evidence gaps
- Request org chart, HRIS export, compensation plans, option grants, attrition data and employee-relations matters.
- Private data-room records are required before relying on this public-source screen for investment or acquisition decisions.
Hidden risks
- Leadership churn may affect execution.
Follow-up questions
- Request org chart, HRIS export, compensation plans, option grants, attrition data and employee-relations matters.
| function or signal | public evidence | risk or gap | verification status |
|---|---|---|---|
| Clinic staffing | Bloomberg summarized staffing crises allegations | Need staffing ratios by clinic and adverse-event logs | inconclusive |
| Leadership expertise | Company claims decades of reproductive medicine and benefits experience | Need resumes, turnover and compensation details | partially_verified |
VII.C Senior management biographies
partially verified confidence: medium
Public team signals are available, but current org chart, compensation, retention, headcount plan and employee-relations records are private.
Evidence gaps
- Request org chart, HRIS export, compensation plans, option grants, attrition data and employee-relations matters.
- Private data-room records are required before relying on this public-source screen for investment or acquisition decisions.
Hidden risks
- Leadership churn may affect execution.
Follow-up questions
- Request org chart, HRIS export, compensation plans, option grants, attrition data and employee-relations matters.
| name or role | title | source signal | diligence caveat |
|---|---|---|---|
| David Stern | CEO | Quoted as CEO in 2026 Kindbody release | Confirm current role, board approvals and succession plan |
| Office of the CEO / prior leadership changes | Reported 2025 temporary structure | Fertility Bridge reported co-chief executive structure and company statement | Need management interview and org chart |
VII.D Compensation arrangements
not publicly verifiable confidence: low
Public team signals are available, but current org chart, compensation, retention, headcount plan and employee-relations records are private.
Evidence gaps
- Request org chart, HRIS export, compensation plans, option grants, attrition data and employee-relations matters.
- Private data-room records are required before relying on this public-source screen for investment or acquisition decisions.
Hidden risks
- Leadership churn may affect execution.
Follow-up questions
- Request org chart, HRIS export, compensation plans, option grants, attrition data and employee-relations matters.
VII.E Incentive stock plans
not publicly verifiable confidence: low
Public team signals are available, but current org chart, compensation, retention, headcount plan and employee-relations records are private.
Evidence gaps
- Request org chart, HRIS export, compensation plans, option grants, attrition data and employee-relations matters.
- Private data-room records are required before relying on this public-source screen for investment or acquisition decisions.
Hidden risks
- Leadership churn may affect execution.
Follow-up questions
- Request org chart, HRIS export, compensation plans, option grants, attrition data and employee-relations matters.
VII.F Significant employee relations problems, past or present
not publicly verifiable confidence: low
Public team signals are available, but current org chart, compensation, retention, headcount plan and employee-relations records are private.
Evidence gaps
- Request org chart, HRIS export, compensation plans, option grants, attrition data and employee-relations matters.
- Private data-room records are required before relying on this public-source screen for investment or acquisition decisions.
Hidden risks
- Leadership churn may affect execution.
Follow-up questions
- Request org chart, HRIS export, compensation plans, option grants, attrition data and employee-relations matters.
VII.G Personnel Turnover
not publicly verifiable confidence: low
Public team signals are available, but current org chart, compensation, retention, headcount plan and employee-relations records are private.
Evidence gaps
- Request org chart, HRIS export, compensation plans, option grants, attrition data and employee-relations matters.
- Private data-room records are required before relying on this public-source screen for investment or acquisition decisions.
Hidden risks
- Leadership churn may affect execution.
Follow-up questions
- Request org chart, HRIS export, compensation plans, option grants, attrition data and employee-relations matters.
08Legal and Related Matters
Legal, regulatory, IP, privacy, insurance and material-contract exposure cannot be cleared from public sources alone.
VIII.A Pending lawsuits against the Company
not publicly verifiable confidence: low
Legal, regulatory, IP, privacy, insurance and material-contract exposure cannot be cleared from public sources alone.
Evidence gaps
- Request litigation docket search, regulatory correspondence, IP schedule, privacy/security audits, insurance policies and material contracts.
- Private data-room records are required before relying on this public-source screen for investment or acquisition decisions.
Hidden risks
- Clinical, privacy and reputational issues require counsel review.
Follow-up questions
- Request litigation docket search, regulatory correspondence, IP schedule, privacy/security audits, insurance policies and material contracts.
VIII.B Pending lawsuits initiated by Company
not publicly verifiable confidence: low
Legal, regulatory, IP, privacy, insurance and material-contract exposure cannot be cleared from public sources alone.
Evidence gaps
- Request litigation docket search, regulatory correspondence, IP schedule, privacy/security audits, insurance policies and material contracts.
- Private data-room records are required before relying on this public-source screen for investment or acquisition decisions.
Hidden risks
- Clinical, privacy and reputational issues require counsel review.
Follow-up questions
- Request litigation docket search, regulatory correspondence, IP schedule, privacy/security audits, insurance policies and material contracts.
VIII.C Environmental and employee safety issues and liabilities
not publicly verifiable confidence: low
Legal, regulatory, IP, privacy, insurance and material-contract exposure cannot be cleared from public sources alone.
Evidence gaps
- Request litigation docket search, regulatory correspondence, IP schedule, privacy/security audits, insurance policies and material contracts.
- Private data-room records are required before relying on this public-source screen for investment or acquisition decisions.
Hidden risks
- Clinical, privacy and reputational issues require counsel review.
Follow-up questions
- Request litigation docket search, regulatory correspondence, IP schedule, privacy/security audits, insurance policies and material contracts.
VIII.D Material patents, copyrights, licenses, and trademarks
partially verified confidence: medium
Legal, regulatory, IP, privacy, insurance and material-contract exposure cannot be cleared from public sources alone.
Evidence gaps
- Request litigation docket search, regulatory correspondence, IP schedule, privacy/security audits, insurance policies and material contracts.
- Private data-room records are required before relying on this public-source screen for investment or acquisition decisions.
Hidden risks
- Clinical, privacy and reputational issues require counsel review.
Follow-up questions
- Request litigation docket search, regulatory correspondence, IP schedule, privacy/security audits, insurance policies and material contracts.
| asset or contract | public signal | missing private record | verification status |
|---|---|---|---|
| Kindbody brand and clinical platform | Company-owned site and platform release | Trademark/IP schedule, software ownership and clinical app vendor contracts | not_publicly_verifiable |
| HIPAA/privacy/security obligations | Company pages link HIPAA Privacy and Data Processing notices | Security audits, BAAs, incident logs, insurance policies | not_publicly_verifiable |
VIII.E Insurance coverage and material exposures
not publicly verifiable confidence: low
Legal, regulatory, IP, privacy, insurance and material-contract exposure cannot be cleared from public sources alone.
Evidence gaps
- Request litigation docket search, regulatory correspondence, IP schedule, privacy/security audits, insurance policies and material contracts.
- Private data-room records are required before relying on this public-source screen for investment or acquisition decisions.
Hidden risks
- Clinical, privacy and reputational issues require counsel review.
Follow-up questions
- Request litigation docket search, regulatory correspondence, IP schedule, privacy/security audits, insurance policies and material contracts.
VIII.F Material contracts
not publicly verifiable confidence: low
Legal, regulatory, IP, privacy, insurance and material-contract exposure cannot be cleared from public sources alone.
Evidence gaps
- Request litigation docket search, regulatory correspondence, IP schedule, privacy/security audits, insurance policies and material contracts.
- Private data-room records are required before relying on this public-source screen for investment or acquisition decisions.
Hidden risks
- Clinical, privacy and reputational issues require counsel review.
Follow-up questions
- Request litigation docket search, regulatory correspondence, IP schedule, privacy/security audits, insurance policies and material contracts.
VIII.G Regulatory agency problems
partially verified confidence: medium
Legal, regulatory, IP, privacy, insurance and material-contract exposure cannot be cleared from public sources alone.
Evidence gaps
- Request litigation docket search, regulatory correspondence, IP schedule, privacy/security audits, insurance policies and material contracts.
- Private data-room records are required before relying on this public-source screen for investment or acquisition decisions.
Hidden risks
- Clinical, privacy and reputational issues require counsel review.
Follow-up questions
- Request litigation docket search, regulatory correspondence, IP schedule, privacy/security audits, insurance policies and material contracts.
| matter | jurisdiction | status or public signal | diligence request |
|---|---|---|---|
| Clinical quality and patient-safety allegations | United States | Bloomberg investigation summary; not a docket | Counsel/clinical quality review and insurance claims history |
| Clinic closures/consolidations and valuation reporting | United States | Fertility Bridge article includes company dispute/response | Board minutes, communications plan, clinic-level P&Ls and lease obligations |
Evidence
| ID | Claim | Status | Sources |
|---|---|---|---|
| EC-001 | CB Insights lists Kindbody as a $1.80B private unicorn. | partially verified high | SRC-001 |
| EC-002 | Kindbody operates fertility and family-building care services through clinics and virtual care. | verified high | SRC-002SRC-003 |
| EC-003 | Kindbody publicly markets employer, health-plan and individual channels. | partially verified medium | SRC-004 |
| EC-004 | Kindbody announced an AI-enabled next-generation fertility platform and 2027 savings model. | partially verified medium | SRC-004 |
| EC-005 | Kindbody says it has raised more than $315M in debt and equity funding. | partially verified medium | SRC-004 |
| EC-006 | Kindbody public pages identify leadership and clinical expertise, but current management structure needs confirmation. | partially verified medium | SRC-003SRC-005 |
| EC-007 | Independent sources report clinic closures, financial pressure and clinical-quality allegations at Kindbody. | inconclusive medium | SRC-005SRC-006 |
| EC-008 | Core financial, customer, HR, legal and contract records are not publicly verifiable. | not publicly verifiable high | SRC-001 |
| EC-009 | Kindbody product pipeline includes AI, medication management, pregnancy support, menopause and savings-model initiatives. | partially verified medium | SRC-004 |
| ID | Publisher | Title | Accessed |
|---|---|---|---|
| SRC-001 | CB Insights | The Complete List Of Unicorn Companies | 2026-06-13 |
| SRC-002 | Kindbody | Kindbody homepage | 2026-06-13 |
| SRC-003 | Kindbody | Kindbody about page | 2026-06-13 |
| SRC-004 | PR Newswire / Kindbody | Kindbody unveils next-generation fertility platform | 2026-06-13 |
| SRC-005 | Fertility Bridge / Inside Reproductive Health | Kindbody Tries to Raise $75M As It Shutters Clinics, Shuffles C-Suite | 2026-06-13 |
| SRC-006 | Bloomberg | IVF Disrupted, The Kindbody Story | 2026-06-13 |
Disclaimer
This report is a public-evidence diligence snapshot, not investment advice. Important financial, legal, technical, and contractual facts remain non-public and should be verified directly with management and primary documents before any investment decision.